

APPENDIX 2: Full Collection of Data for the Backbone Ester Mutation at L119 in the $\alpha 4\beta 2$ and Muscle-Type Nicotinic Acetylcholine Receptors (nAChRs)

This appendix compiles all of the data from Chapters 2-4 concerning the backbone ester mutation at L119 in the complementary subunit of $\alpha 4\beta 2$ and the muscle-type nAChRs.

Key observations:

1. The largest fold shift is seen for (-)-Cytisine at the $(\alpha 4)_2(\beta 2)_3$ receptor despite its low efficacy for this receptor (~0.03 relative to ACh).
2. Varenicline is unaffected by this mutation at both stoichiometries of $\alpha 4\beta 2$.
3. Epibatidine is sensitive to the backbone ester mutation in $\alpha 4\beta 2$ but not in the muscle-type receptor.
4. In general, larger fold-shifts are seen in the muscle-type receptor than in $\alpha 4\beta 2$.
5. The $\alpha 1G153K$ mutation has little impact on the L119 interaction.
6. The weak agonist choline (which does not contain the hydrogen bond acceptor of the pharmacophore) is unaffected by the backbone ester mutation, but the nicotine analog *S*-MPP gives a large gain-of-function in the $\alpha 4\beta 2$ receptor.

Table A2.1. EC₅₀ values, Hill coefficients, and relative efficacies for the muscle-type receptor. Errors are standard error of the mean. Mutations identified as “Leu” represent recovery of the wild-type receptor by nonsense suppression.

Agonist	Mutation	EC₅₀ (nM)	Fold-Shift	Hill (n_H)
$\alpha_1\beta_1\gamma\delta$				
ACh	$\alpha_1\beta_1\gamma\delta$	16000 ± 300		1.3 ± 0.1
	$\alpha_1\beta_1\gamma(L119Leu)\delta(L121Leu)$	16000 ± 500		1.5 ± 0.1
	$\alpha_1\beta_1\gamma(L119Lah)\delta(L121Lah)$	230000 ± 6000	14	1.5 ± 0.1
$\alpha_1\beta_1(L9'S)\gamma\delta$				
ACh	$\alpha_1\beta_1(L9'S)\gamma\delta$	610 ± 40		1.4 ± 0.1
	$\alpha_1\beta_1(L9'S)\gamma(L119Leu)\delta(L121Leu)$	310 ± 20		1.5 ± 0.1
	$\alpha_1\beta_1(L9'S)\gamma(L119Lah)\delta(L121Lah)$	9100 ± 700	29	1.6 ± 0.2
Ch	$\alpha_1\beta_1(L9'S)\gamma\delta$	840000 ± 20000		1.6 ± 0.1
	$\alpha_1\beta_1(L9'S)\gamma(L119Leu)\delta(L121Leu)$	780000 ± 30000		1.7 ± 0.1
	$\alpha_1\beta_1(L9'S)\gamma(L119Lah)\delta(L121Lah)$	1000000 ± 50	1.3	1.8 ± 0.1
S-Nic	$\alpha_1\beta_1(L9'S)\gamma\delta$	22000 ± 800		1.6 ± 0.1
	$\alpha_1\beta_1(L9'S)\gamma(L119Leu)\delta(L121Leu)$	23000 ± 700		1.7 ± 0.1
	$\alpha_1\beta_1(L9'S)\gamma(L119Lah)\delta(L121Lah)$	230000 ± 30000	10	2.2 ± 0.5
(\pm) -Epi	$\alpha_1\beta_1(L9'S)\gamma\delta$	320 ± 20		1.5 ± 0.1
	$\alpha_1\beta_1(L9'S)\gamma(L119Leu)\delta(L121Leu)$	400 ± 20		1.5 ± 0.1
	$\alpha_1\beta_1(L9'S)\gamma(L119Lah)\delta(L121Lah)$	520 ± 30	1.3	1.6 ± 0.1
$\alpha_1(G153K)_2\beta_1(L9'S)\gamma\delta$				
ACh	$\alpha_1(G153K)\beta_1(L19'S)\gamma\delta$	7.2 ± 0.7		1.3 ± 0.1
	$\alpha_1(G153K)\beta_1(L9'S)\gamma(L119Leu)\delta(L121Leu)$	7.6 ± 0.7		1.8 ± 0.3
	$\alpha_1(G153K)\beta_1(L9'S)\gamma(L119Lah)\delta(L121Lah)$	180 ± 20	24	1.3 ± 0.1
Ch	$\alpha_1(G153K)\beta_1(L19'S)\gamma\delta$	30000 ± 2000		1.0 ± 0.1
	$\alpha_1(G153K)\beta_1(L9'S)\gamma(L119Leu)\delta(L121Leu)$	27000 ± 2000		1.1 ± 0.1
	$\alpha_1(G153K)\beta_1(L9'S)\gamma(L119Lah)\delta(L121Lah)$	68000 ± 3000	2.5	1.3 ± 0.1
S-Nic	$\alpha_1(G153K)\beta_1(L19'S)\gamma\delta$	320 ± 30		1.4 ± 0.2
	$\alpha_1(G153K)\beta_1(L9'S)\gamma(L119Leu)\delta(L121Leu)$	360 ± 40		0.95 ± 0.1
	$\alpha_1(G153K)\beta_1(L9'S)\gamma(L119Lah)\delta(L121Lah)$	6500 ± 500	18	1.3 ± 0.1
(\pm) -Epi	$\alpha_1(G153K)\beta_1(L19'S)\gamma\delta$	4.3 ± 0.5		0.77 ± 0.5
	$\alpha_1(G153K)\beta_1(L9'S)\gamma(L119Leu)\delta(L121Leu)$	2.3 ± 0.4		0.74 ± 0.1
	$\alpha_1(G153K)\beta_1(L9'S)\gamma(L119Lah)\delta(L121Lah)$	9.6 ± 0.4	4.2	1.1 ± 0.1

Table A2.2. EC₅₀ values, Hill coefficients, and relative efficacies for the $\alpha 4\beta 2$ receptor. All studies gave current values at +70 mV (normalized to -110 mV) of ≤ 0.08 or > 0.2 , confirming the A2B3 or A3B2 stoichiometry, respectively. Errors are standard error of the mean. Mutations identified as “Leu” represent recovery of the wild-type receptor by nonsense suppression. The relative efficacy is the ratio of the I_{max} of a saturating concentration of agonist / I_{max} of a saturating concentration of ACh. By definition, the relative efficacy of ACh is 1.

Agonist	Mutation	EC ₅₀ (nM)	Fold-Shift	Hill (n _H)	Relative Efficacy
$\alpha 4(L9'A)_2\beta 2_3$					
ACh	$\alpha 4(L9'A)\beta 2$	360 \pm 20		1.3 \pm 0.1	[1]
	$\alpha 4(L9'A)\beta 2(L119Leu)$	440 \pm 20		1.3 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	3000 \pm 100	6.8	1.2 \pm 0.1	
CCh	$\alpha 4(L9'A)\beta 2$	7200 \pm 80		1.3 \pm 0.1	0.50 \pm 0.02
	$\alpha 4(L9'A)\beta 2(L119Leu)$	7900 \pm 200		1.2 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	29000 \pm 800	3.7	1.2 \pm 0.1	
Ch	$\alpha 4(L9'A)\beta 2$	140000 \pm 4000		1.6 \pm 0.1	0.060 \pm 0.01
	$\alpha 4(L9'A)\beta 2(L119Leu)$	135000 \pm 20000		1.2 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	150000 \pm 5000	1.1	1.4 \pm 0.1	
S-Nic	$\alpha 4(L9'A)\beta 2$	120 \pm 5		1.3 \pm 0.1	0.27 \pm 0.01
	$\alpha 4(L9'A)\beta 2(L119Leu)$	120 \pm 3		1.5 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	800 \pm 30	6.7	1.3 \pm 0.1	
S-MPP	$\alpha 4(L9'A)\beta 2$	11000 \pm 400		1.7 \pm 0.1	0.23 \pm 0.01
	$\alpha 4(L9'A)\beta 2(L119Leu)$	14000 \pm 900		1.5 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	1100 \pm 40	0.1	1.5 \pm 0.1	
(R/S)-MPP	$\alpha 4(L9'A)\beta 2$	19000 \pm 600		1.8 \pm 0.1	0.14 \pm 0.02
(\pm)-Epi	$\alpha 4(L9'A)\beta 2$	0.79 \pm 0.04		1.4 \pm 0.1	0.47 \pm 0.03
	$\alpha 4(L9'A)\beta 2(L119Leu)$	0.58 \pm 0.05		1.5 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	2.9 \pm 0.1	5.0	1.3 \pm 0.1	
(+)-Epi	$\alpha 4(L9'A)\beta 2$	0.87 \pm 0.03		1.5 \pm 0.1	0.33 \pm 0.01
	$\alpha 4(L9'A)\beta 2(L119Leu)$	0.58 \pm 0.04		1.3 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	2.7 \pm 0.1	4.7	1.3 \pm 0.1	
(-)-Epi	$\alpha 4(L9'A)\beta 2$	1.1 \pm 0.04		1.6 \pm 0.1	0.74 \pm 0.03
	$\alpha 4(L9'A)\beta 2(L119Leu)$	0.73 \pm 0.03		1.4 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	3.8 \pm 0.2	5.2	1.1 \pm 0.1	
(+)-Epi-Me	$\alpha 4(L9'A)\beta 2$	8.6 \pm 0.5		1.7 \pm 0.2	0.50 \pm 0.03
	$\alpha 4(L9'A)\beta 2(L119Leu)$	8.9 \pm 0.7		1.3 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	30 \pm 2	3.4	1.4 \pm 0.1	
(-)-Epi-Me	$\alpha 4(L9'A)\beta 2$	0.42 \pm 0.04		1.5 \pm 0.1	0.55 \pm 0.03
	$\alpha 4(L9'A)\beta 2(L119Leu)$	0.42 \pm 0.04		1.6 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	0.91 \pm 0.06	2.2	1.9 \pm 0.2	
Cy	$\alpha 4(L9'A)\beta 2$	6.9 \pm 0.3		1.4 \pm 0.1	0.030 \pm 0.01
	$\alpha 4(L9'A)\beta 2(L119Leu)$	8.7 \pm 0.4		1.2 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	540 \pm 30	62	0.98 \pm 0.1	
Var	$\alpha 4(L9'A)\beta 2$	3.1 \pm 0.1		1.4 \pm 0.1	0.12 \pm 0.02
	$\alpha 4(L9'A)\beta 2(L119Leu)$	2.6 \pm 0.2		1.3 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	4.7 \pm 0.2	1.8	1.3 \pm 0.1	
$\alpha 4(L9'A)_3\beta 2_2$					
ACh	$\alpha 4(L9'A)\beta 2$	26 \pm 0.1		1.1 \pm 0.1	[1]
	$\alpha 4(L9'A)\beta 2(L119Leu)$	26 \pm 0.4		1.6 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	220 \pm 10	8.5	1.2 \pm 0.1	
Ch	$\alpha 4(L9'A)\beta 2$	90000 \pm 2000		1.4 \pm 0.1	0.70 \pm 0.06
	$\alpha 4(L9'A)\beta 2(L119Leu)$	76000 \pm 200		1.4 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	74000 \pm 2000	1.0	1.5 \pm 0.1	
S-Nic	$\alpha 4(L9'A)\beta 2$	12 \pm 0.1		1.6 \pm 0.1	0.56 \pm 0.04
	$\alpha 4(L9'A)\beta 2(L119Leu)$	12 \pm 0.1		1.6 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	67 \pm 3	5.6	1.4 \pm 0.1	
S-MPP	$\alpha 4(L9'A)\beta 2$	4500 \pm 100		1.1 \pm 0.1	0.39 \pm 0.03
	$\alpha 4(L9'A)\beta 2(L119Leu)$	4200 \pm 300		1.6 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	130 \pm 10	0.031	1.2 \pm 0.1	
(R/S)-MPP	$\alpha 4(L9'A)\beta 2$	5900 \pm 100		1.6 \pm 0.1	0.28 \pm 0.03
Cy	$\alpha 4(L9'A)\beta 2$	3.1 \pm 0.1		1.9 \pm 0.1	0.54 \pm 0.05
	$\alpha 4(L9'A)\beta 2(L119Leu)$	3.6 \pm 0.1		1.9 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	51 \pm 2	14	1.4 \pm 0.1	
Var	$\alpha 4(L9'A)\beta 2$	0.95 \pm 0.02		1.7 \pm 0.1	0.33 \pm 0.01
	$\alpha 4(L9'A)\beta 2(L119Leu)$	1.0 \pm 0.1		1.5 \pm 0.1	
	$\alpha 4(L9'A)\beta 2(L119Lah)$	1.1 \pm 0.1	1.1	1.2 \pm 0.1	